{"title":"Sex Differences in Suicide Mortality: Epidemiology, Modifying Factors, and Clinical Implications. A Narrative Review.","authors":"Robert Rudolf Becker","doi":"10.3238/arztebl.m2026.0136","DOIUrl":"10.3238/arztebl.m2026.0136","url":null,"abstract":"<p><strong>Background: </strong>In Western industrialized nations, the sexes differ in suicide mortality and the prevalence of diagnosed depression. Men have a higher mortality from suicide than women (figures for Germany, 2024: 18.2 vs. 6.9 per 100 000), but the 12-month prevalence of clinically diagnosed depression in women is double that in men (10-12% vs. 5-6%). This situation has been called the gender paradox in suicide. In this article, we present a structured analysis of the relevant sex-specific epidemiology and the modifying factors that account for these findings.</p><p><strong>Methods: </strong>This narrative review was created according to the SANRA recommendations on the basis of publications retrieved by a selective search in the PubMed and Cochrane Library databases (2000–2026) and the cause-of-death statistics of the German Federal Statistical Office (2003–2024).</p><p><strong>Results: </strong>In 2024, the suicide rate in Germany was 18.2 per 100 000 men (n = 7414) and 6.9 per 100 000 women (n = 2958). The relative risk for suicide in men is higher by a factor of 2.6 (95% CI: [2.5; 2.8]). Affective disorders are associated with ca. 90% of all suicides, although psychological autopsy studies are subject to methodological limitations, including recall bias. Men over age 85 are particularly vulnerable, with a suicide rate of 45.7 per 100 000. Modifying factors contributing to this sex disparity include the choice of more lethal means of suicide (e.g., hanging, which accounts for 50.5% of male suicides) and an often unrecognized, externalizing depression in men.</p><p><strong>Conclusion: </strong>It may be possible to lower mortality from suicide in men through greater sensitivity for sex-specific symptomatic presentations, greater attention to somatic risk factors in old age, and implementation of low-threshold, sex-sensitive preventive measures.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":"123 22","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sorin S Popescu, Felix Behn, Charlotte Eitel, Jan-Per Wenzel, Sascha Hatahet, Roman Mamaev, Bianca I Popescu, Anna Traub, Suzanne de Waha, Julia Vogler, Christian-H Heeger, Mirco Küchler, Karl-H Kuck, Roland R Tilz
{"title":"Same-Day Discharge Versus Overnight Stay After Catheter Ablation: An Observational Matched-Cohort Study on Safety and Feasibility.","authors":"Sorin S Popescu, Felix Behn, Charlotte Eitel, Jan-Per Wenzel, Sascha Hatahet, Roman Mamaev, Bianca I Popescu, Anna Traub, Suzanne de Waha, Julia Vogler, Christian-H Heeger, Mirco Küchler, Karl-H Kuck, Roland R Tilz","doi":"10.3238/arztebl.m2026.0148","DOIUrl":"10.3238/arztebl.m2026.0148","url":null,"abstract":"<p><strong>Background: </strong>Catheter ablation is an established therapy for arrhythmias. As the incidence of atrial fibrillation (AF) rises, the associated burden on the health-care system is expected to increase. Same-day discharge (SDD) may help optimize resource utilization and increase patient comfort and satisfaction.</p><p><strong>Methods: </strong>Consecutive patients undergoing SDD electrophysiology procedures were prospectively enrolled in the study and compared in a non-randomized manner with consecutive overnight stay (ONS) patients who were matched to them according to procedure type. SDD patients were evaluated on the day after the procedure. SDD Patients who were not discharged on the day of the procedure were excluded. Baseline, periprocedural, and 30-day outcomes were documented and compared.</p><p><strong>Results: </strong>100 patients underwent SDD electrophysiology procedures from September 2022 to March 2025. The SDD patients were younger and had a lower prevalence of coronary artery disease and chronic kidney disease than their counterparts in the ONS cohort. The most common procedure was AF ablation. Procedural complications arose in 2% (95% confidence interval: [0.6; 7.0]) vs. 6% [2.8; 12.5] in SDD and ONS patients, respectively, p =0.279. Complications up to the day of discharge, or up to the evaluation on post-procedure day 1 in the SDD group were reported in 10% [5.5; 17.4] and 17% [10.9, 25.6] of patients, respectively, p = 0.214. Complications were identified on post-procedure day 1 in 8 SDD patients, none of whom needed to be readmitted to the hospital. The numbers of emergency room consultations, unplanned outpatient visits, and rehospitalizations were similar in the two groups. In a subsequent analysis from January to May 2026, 85.8% of patients scheduled for SDD ablation were successfully discharged on the day of the procedure.</p><p><strong>Conclusion: </strong>In this prospective study, SDD after electrophysiology procedures was found to be a safe alternative to ONS in selected patients. None of the patients who were discharged on the same day as the procedure needed to be rehospitalized on the day after.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":"123 22","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Consumption of Energy Drinks Among Adolescents: Findings of the \"Prevention Radar\" Survey, 2020-2026.","authors":"Julia Hansen, Clemens Neumann, Reiner Hanewinkel","doi":"10.3238/arztebl.m2026.0129","DOIUrl":"10.3238/arztebl.m2026.0129","url":null,"abstract":"","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":"123 20","pages":"567-568"},"PeriodicalIF":8.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13686098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Subclinical Atrial Fibrillation: Detection, Stroke Risk, and Treatment.","authors":"Michael Gotzmann, Fabienne Kreimer","doi":"10.3238/arztebl.m2026.0125","DOIUrl":"10.3238/arztebl.m2026.0125","url":null,"abstract":"<p><strong>Background: </strong>Clinically evident atrial fibrillation is estimated to affect more than 1.8 million people in Germany. Atrial arrhythmias are increasingly being detected by cardiac devices and wearables in asymptomatic persons without any history of atrial fibrillation. Such cases are usually designated as \"subclinical atrial fibrillation.\" With the limited and, in part, inconsistent evidence now available, it remains unclear whether this condition is medically relevant and an indication for oral anticoagulation.</p><p><strong>Methods: </strong>This review is based on pertinent publications (2005-2025) retrieved by a selective search in the PubMed, Embase, and Cochrane Library databases on subclinical atrial fibrillation, atrial high-rate episodes (AHRE), and device- or wearable-detected atrial fibrillation.</p><p><strong>Results: </strong>Subclinical atrial fibrillation is associated with an elevated risk of stroke that increases with episode duration and arrhythmia burden. Observational studies have shown that device-detected episodes lasting 6 minutes or longer elevate the stroke risk by a factor of 2 to 2.5, yielding an absolute risk that is still lower than that of patients with clinically evident atrial fibrillation. No direct causal or temporal relationship has been shown between the detected episodes and thromboembolic events. Screening increases the detection rate without improving outcomes. Randomized trials (LOOP, NOAH-AFNET 6, ARTESiA) have not revealed any consistent clinical benefit from routine oral anticoagulation. In the ARTESiA trial, patients taking apixaban had fewer strokes (hazard ratio 0.63, 95% confidence interval [0.45; 0.88]), but also significantly more clinically relevant hemorrhages (HR 1.80 [1.26; 2.7]). In the NOAH-AFNET 6 trial, edoxaban was not found to have any benefit, but it did elevate the risk of bleeding.</p><p><strong>Conclusion: </strong>Routine oral anticoagulation cannot currently be recommended for patients with subclinical atrial fibrillation. Important considerations for treatment decisions include the individual thromboembolic risk profile, the duration and burden of subclinical atrial fibrillation, and the reliability of the diagnosis. Current evidence suggests that subclinical atrial fibrillation is more likely to be a marker for underlying atrial cardiomyopathy than a direct precipitant of thromboembolic events.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":"123 20","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frank Rommel, Christa Bergheim, Ralph Melchior, Thomas Krause, Matthias Zilbauer, Andreas Jenke
{"title":"Refractory Chronic Inflammatory Bowel Disease in Childhood and Adolescence: Options in Primary Non-Response or Secondary Treatment Failure.","authors":"Frank Rommel, Christa Bergheim, Ralph Melchior, Thomas Krause, Matthias Zilbauer, Andreas Jenke","doi":"10.3238/arztebl.m2026.0128","DOIUrl":"10.3238/arztebl.m2026.0128","url":null,"abstract":"<p><strong>Background: </strong>The incidence of inflammatory bowel disease among children and adolescents in Europe is approximately 10 per 100.000 per year. Refractory disease courses are clinically significant and associated with delayed growth and development, recurrent hospitalizations, and the need for surgery. 10–40% of patients have a primary nonresponse to anti-TNFα therapies, and a further 5–20% per year have secondary treatment failure, defined as loss of response after an initial response while on maintenance treatment. The aim of this review is to summarize current treatment options for primary non-response or secondary treatment failure.</p><p><strong>Method: </strong>This narrative review is based on current guidelines and pertinent publications retrieved by a selective search in the PubMed, Ovid MEDLINE, and Cochrane databases.</p><p><strong>Results: </strong>Before switching to another drug class, a standardized reevaluation is essential, incorporating clinical findings, biomarkers, endoscopy and/or imaging, and therapeutic drug monitoring. Following failure of anti-TNFα therapy, ustekinumab (approved for Crohn’s disease for patients ≥ 2 years of age) and vedolizumab (currently exclusively off-label) represent the best-established options in pediatric care. Reported clinical remission rates are 51% at week 52 for ustekinumab and 32% (Crohn’s disease) and 42% (ulcerative colitis) at week 14 for vedolizumab. For IL-23p19 antibodies, Janus kinase inhibitors, and sphingo-sine-1-phosphate receptor modulators, the available evidence is still derived predominantly from adult studies, with very limited data from pediatric practice. Surgery remains an important option in complicated disease courses.</p><p><strong>Conclusion: </strong>Given the limited pediatric evidence and the frequent off-label use of newer agents, there is a need for prospective studies, registry data, and structured treatment algorithms to more reliably define the efficacy and long-term safety of treatments for pediatric chronic inflammatory bowel disease. In our view, children and adolescents with refractory inflammatory bowel disease should be managed by an interdisciplinary team in a center with the requisite experience.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":"123 20","pages":"550-557"},"PeriodicalIF":8.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}